As for AP-1 TFs, we show that they are the core TFs in the transcriptional network during the neurogenic-to-gliogenic switch, and transient AP-1 inhibition at this stage with T5224, a drug not previously used for the treatment of malignant glioma, is sufficient to inhibit gliomagenesis in vivo and provide survival benefits. Here, JUN is linked to malignant glioma.